Earnings call transcript: Beachbody Q1 2026 sees profitability amid revenue fall

Beachbody delivered its third consecutive quarter of profitability, with Q1 revenue of $54.3 million, net income of $2.3 million versus a $5.7 million loss a year ago, and adjusted EBITDA of $8.0 million. Gross margin remained strong at 71.8%, while management highlighted new retail distribution wins for Shakeology at Sprouts, KeHE, and The Vitamin Shoppe and guided Q2 revenue to $46 million-$51 million. Shares rose 5.8% premarket to $13.31, though the company still faces revenue declines and near-term pressure from the ongoing transition away from MLM.

Analysis

The setup is less about a near-term top-line inflection and more about a business-model optionality trade: BODI is converting a shrinking, low-quality revenue base into a higher-ROIC consumer platform with materially better unit economics. The important second-order effect is that retail distribution and marketplace-led nutrition should reduce reliance on paid digital acquisition over time, which can create a flywheel if bundle economics hold; if not, the company risks swapping one form of churn for another, just in a different channel.

The biggest near-term catalyst is not the Q2 guide but proof that retail can scale without destroying mix. KeHE, Sprouts, and Vitamin Shoppe give the company distribution credibility, yet wholesale also compresses control over pricing, promo cadence, and reorder visibility, so the market will quickly re-rate if scan data or retailer expansion stalls. The key watch item is whether nutrition becomes a true cohort business or simply a one-time sell-through event that flatters revenue while recurring subscriptions keep drifting lower.

For competitors, the most likely pressure is on smaller DTC supplement brands and adjacent fitness apps that lack a recognizable brand family plus an owned content engine. BODI’s approach of using nutrition as the top-of-funnel entry point is strategically clever because it attacks a much larger category and lets the fitness product function as a low-friction attach, which is structurally better than trying to sell habit formation first. The market may be underappreciating how much this shifts the company from a subscription SKU to a branded-portfolio story, which could expand valuation multiples if retail velocity proves durable.

The contrarian risk is that consensus is extrapolating early margin discipline into durable earnings power before the channel mix is proven. The operating leverage is real, but the next 2-3 quarters are still transition quarters; any inventory adjustment, promo misstep, or slower-than-expected national reset pipeline could quickly unwind sentiment. The right lens is months, not days: this is a small-cap execution story with a potentially large 2027 payoff, but also a high dispersion setup where one bad retail read can cut the multiple fast.

Key Decisions for Investors

• Long BODI into pullbacks over the next 2-6 weeks, targeting a 20-30% upside move if retail rollout updates and Q3 burn-off confirm cleaner comparisons; risk is a 15%+ drawdown if the market discounts the guide as transition-only.
• Buy BODI calls 3-6 months out rather than common stock if liquidity allows; the best payoff comes from a discrete catalyst stack around retail partner additions, with defined downside versus common-equity volatility.
• Pair trade: long BODI / short a basket of small-cap DTC fitness or supplement names with weaker brand recognition; the thesis is that BODI’s omni-channel distribution and content library create a better path to CAC leverage than pure-play peers.
• Sell strength after the first post-earnings pop unless channel checks confirm meaningful shelf expansion; this is a good trade only if wholesale velocity data starts validating the retail story.
• Monitor SHOP and AMZN as secondary beneficiaries: if BODI’s Shopify conversion and marketplace attach rates improve, the highest-probability indirect winners are commerce infrastructure rather than media peers.